Lin-Jie Zhang, De-Cai Tian, Li Yang, Kaibin Shi, Yaou Liu, Yilong Wang, Fu-Dong Shi
Damage or microstructural alterations of the white matter can cause dysfunction of the intrinsic neural networks in a condition termed as white matter disease (WMD). Frequently detected on brain computed tomography and magnetic resonance imaging scans, WMD is commonly presented in inflammatory demyelinating diseases like multiple sclerosis (MS) and vascular diseases such as cerebral small vessel disease (CSVD). Prevention of MS and CSVD progression requires early treatments with drastically different medications and approaches, as such, early and accurate diagnosis of WMD, derived from vascular or demyelinating etiologies, is of paramount importance. However, the clinical and imaging similarities between MS, especially during the early stage, and CSVD, pose a significant dilemma in differentiating these two conditions. In this review, we attempt to summarize and contrast the distinguishing features of MS and CSVD for aiding accurate diagnosis to ensure timely corresponding management in the early stages of MS and CSVD.
{"title":"White matter disease derived from vascular and demyelinating origins.","authors":"Lin-Jie Zhang, De-Cai Tian, Li Yang, Kaibin Shi, Yaou Liu, Yilong Wang, Fu-Dong Shi","doi":"10.1136/svn-2023-002791","DOIUrl":"10.1136/svn-2023-002791","url":null,"abstract":"<p><p>Damage or microstructural alterations of the white matter can cause dysfunction of the intrinsic neural networks in a condition termed as white matter disease (WMD). Frequently detected on brain computed tomography and magnetic resonance imaging scans, WMD is commonly presented in inflammatory demyelinating diseases like multiple sclerosis (MS) and vascular diseases such as cerebral small vessel disease (CSVD). Prevention of MS and CSVD progression requires early treatments with drastically different medications and approaches, as such, early and accurate diagnosis of WMD, derived from vascular or demyelinating etiologies, is of paramount importance. However, the clinical and imaging similarities between MS, especially during the early stage, and CSVD, pose a significant dilemma in differentiating these two conditions. In this review, we attempt to summarize and contrast the distinguishing features of MS and CSVD for aiding accurate diagnosis to ensure timely corresponding management in the early stages of MS and CSVD.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"344-350"},"PeriodicalIF":4.4,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10572132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Songchun Yang, Zhijia Sun, Dong Sun, Canqing Yu, Yu Guo, Dianjianyi Sun, Yuanjie Pang, Pei Pei, Ling Yang, Iona Y Millwood, Robin G Walters, Yiping Chen, Huaidong Du, Yan Lu, Sushila Burgess, Daniel Avery, Robert Clarke, Junshi Chen, Zhengming Chen, Liming Li, Jun Lv
Background and purpose: Previous studies, mostly focusing on the European population, have reported polygenic risk scores (PRSs) might achieve risk stratification of stroke. We aimed to examine the association strengths of PRSs with risks of stroke and its subtypes in the Chinese population.
Methods: Participants with genome-wide genotypic data in China Kadoorie Biobank were split into a potential training set (n=22 191) and a population-based testing set (n=72 150). Four previously developed PRSs were included, and new PRSs for stroke and its subtypes were developed. The PRSs showing the strongest association with risks of stroke or its subtypes in the training set were further evaluated in the testing set. Cox proportional hazards regression models were used to estimate the association strengths of different PRSs with risks of stroke and its subtypes (ischaemic stroke (IS), intracerebral haemorrhage (ICH) and subarachnoid haemorrhage (SAH)).
Results: In the testing set, during 872 919 person-years of follow-up, 8514 incident stroke events were documented. The PRSs of any stroke (AS) and IS were both positively associated with risks of AS, IS and ICH (p<0.05). The HR for per SD increment (HRSD) of PRSAS was 1.10 (95% CI 1.07 to 1.12), 1.10 (95% CI 1.07 to 1.12) and 1.13 (95% CI 1.07 to 1.20) for AS, IS and ICH, respectively. The corresponding HRSD of PRSIS was 1.08 (95% CI 1.06 to 1.11), 1.08 (95% CI 1.06 to 1.11) and 1.09 (95% CI 1.03 to 1.15). PRSICH was positively associated with the risk of ICH (HRSD=1.07, 95% CI 1.01 to 1.14). PRSSAH was not associated with risks of stroke and its subtypes. The addition of current PRSs offered little to no improvement in stroke risk prediction and risk stratification.
Conclusions: In this Chinese population, the association strengths of current PRSs with risks of stroke and its subtypes were moderate, suggesting a limited value for improving risk prediction over traditional risk factors in the context of current genome-wide association study under-representing the East Asian population.
背景和目的:以往的研究大多集中在欧洲人群,这些研究报告称多基因风险评分(PRSs)可实现脑卒中的风险分层。我们旨在研究多基因风险评分与中国人群中风风险及其亚型的关联强度:方法:将中国嘉道理生物库中拥有全基因组基因型数据的参与者分为潜在训练集(22 191 人)和基于人群的测试集(72 150 人)。其中包括四个以前开发的 PRS,以及针对脑卒中及其亚型开发的新 PRS。在训练集中显示与中风风险或其亚型关系最密切的 PRS 在测试集中得到进一步评估。使用 Cox 比例危险度回归模型估算不同 PRS 与中风及其亚型(缺血性中风(IS)、脑内出血(ICH)和蛛网膜下腔出血(SAH))风险的关联强度:在 872 919 人年的随访过程中,测试组记录了 8514 例中风事件。任何卒中(AS)和 IS 的 PRS 与 AS、IS 和 ICH 的风险均呈正相关(PRSAS 的 pSD 分别为 1.10(95% CI 1.07 至 1.12)、1.10(95% CI 1.07 至 1.12)和 1.13(95% CI 1.07 至 1.20))。PRSIS的相应HRSD分别为1.08(95% CI 1.06至1.11)、1.08(95% CI 1.06至1.11)和1.09(95% CI 1.03至1.15)。PRSICH 与 ICH 风险呈正相关(HRSD=1.07,95% CI 1.01 至 1.14)。PRSSAH 与中风及其亚型的风险无关。增加目前的 PRS 对卒中风险预测和风险分层几乎没有改善:在这一中国人群中,当前 PRS 与脑卒中风险及其亚型的关联强度适中,这表明在当前全基因组关联研究对东亚人群代表性不足的背景下,与传统风险因素相比,当前 PRS 在改善风险预测方面的价值有限。
{"title":"Associations of polygenic risk scores with risks of stroke and its subtypes in Chinese.","authors":"Songchun Yang, Zhijia Sun, Dong Sun, Canqing Yu, Yu Guo, Dianjianyi Sun, Yuanjie Pang, Pei Pei, Ling Yang, Iona Y Millwood, Robin G Walters, Yiping Chen, Huaidong Du, Yan Lu, Sushila Burgess, Daniel Avery, Robert Clarke, Junshi Chen, Zhengming Chen, Liming Li, Jun Lv","doi":"10.1136/svn-2023-002428","DOIUrl":"10.1136/svn-2023-002428","url":null,"abstract":"<p><strong>Background and purpose: </strong>Previous studies, mostly focusing on the European population, have reported polygenic risk scores (PRSs) might achieve risk stratification of stroke. We aimed to examine the association strengths of PRSs with risks of stroke and its subtypes in the Chinese population.</p><p><strong>Methods: </strong>Participants with genome-wide genotypic data in China Kadoorie Biobank were split into a potential training set (n=22 191) and a population-based testing set (n=72 150). Four previously developed PRSs were included, and new PRSs for stroke and its subtypes were developed. The PRSs showing the strongest association with risks of stroke or its subtypes in the training set were further evaluated in the testing set. Cox proportional hazards regression models were used to estimate the association strengths of different PRSs with risks of stroke and its subtypes (ischaemic stroke (IS), intracerebral haemorrhage (ICH) and subarachnoid haemorrhage (SAH)).</p><p><strong>Results: </strong>In the testing set, during 872 919 person-years of follow-up, 8514 incident stroke events were documented. The PRSs of any stroke (AS) and IS were both positively associated with risks of AS, IS and ICH (p<0.05). The HR for per SD increment (HR<sub>SD</sub>) of PRS<sub>AS</sub> was 1.10 (95% CI 1.07 to 1.12), 1.10 (95% CI 1.07 to 1.12) and 1.13 (95% CI 1.07 to 1.20) for AS, IS and ICH, respectively. The corresponding HR<sub>SD</sub> of PRS<sub>IS</sub> was 1.08 (95% CI 1.06 to 1.11), 1.08 (95% CI 1.06 to 1.11) and 1.09 (95% CI 1.03 to 1.15). PRS<sub>ICH</sub> was positively associated with the risk of ICH (HR<sub>SD</sub>=1.07, 95% CI 1.01 to 1.14). PRS<sub>SAH</sub> was not associated with risks of stroke and its subtypes. The addition of current PRSs offered little to no improvement in stroke risk prediction and risk stratification.</p><p><strong>Conclusions: </strong>In this Chinese population, the association strengths of current PRSs with risks of stroke and its subtypes were moderate, suggesting a limited value for improving risk prediction over traditional risk factors in the context of current genome-wide association study under-representing the East Asian population.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"399-406"},"PeriodicalIF":4.4,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10183793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Tenecteplase (TNK) was found non-inferior to alteplase in recent clinical trials. We aimed to elucidate the efficacy and safety of TNK versus alteplase for acute ischaemic stroke (AIS).
Methods: Systematic literature search and a meta-analysis of phase III clinical trials in ischaemic stroke patients with TNK use were conducted. The primary outcome was excellent functional outcome which was defined as modified Rankin Scale score of 0-1 at 90 days and safety outcomes included symptomatic intracerebral haemorrhage and death at 90 days. We used random-effects model to estimate the pooled risk difference and 95% CI in R package 'Meta'. The included trials were adapted to the non-inferiority analysis with a margin of -4%.
Results: Three trials enrolling 4094 patients were identified by systematic search. All trials included AIS patients within 4.5 hours time window. Meta-analysis indicated that 1089 (53.0%) of 2056 patients in the TNK arm and 1016 (50.5%) of 2012 in the alteplase arm had excellent functional outcome at 90 days (0.03 (95% CI -0.00 to 0.06); I2=0%), meeting the prespecified non-inferiority threshold. And TNK thrombolysis was not correlated with increased risk of symptomatic intracerebral haemorrhage (0.00 (95% CI -0.01 to 0.01); I2=0%) or death (0.01 (95% CI -0.01 to 0.02); I2=0%) at 90 days. The sensitivity analysis with the 0.25 mg/kg trials exclusively showed similar results to the main analysis.
Conclusions: TNK was non-inferior to alteplase for achieving excellent functional outcome at 90 days without increasing the safety concern in treating patients with AIS. These findings suggest that TNK can be an alternative to alteplase.
Prospero registration number: CRD42022354342.
背景:在最近的临床试验中发现,特奈替普酶(TNK)的疗效并不优于阿替普酶。我们旨在阐明 TNK 与阿替普酶治疗急性缺血性卒中(AIS)的疗效和安全性:方法:对使用 TNK 的缺血性脑卒中患者的 III 期临床试验进行了系统的文献检索和荟萃分析。主要研究结果为90天后的良好功能预后,即修改后的Rankin量表评分为0-1分;安全性研究结果包括90天后的无症状性脑内出血和死亡。我们在 R 软件包 "Meta "中使用随机效应模型估算了汇总风险差异和 95% CI。对纳入的试验进行了非劣效性分析,差值为-4%:结果:通过系统检索,确定了三项试验,共纳入 4094 名患者。所有试验都纳入了 4.5 小时时间窗内的 AIS 患者。荟萃分析表明,TNK治疗组2056例患者中的1089例(53.0%)和阿替普酶治疗组2012例患者中的1016例(50.5%)在90天时具有极佳的功能预后(0.03(95% CI -0.00至0.06);I2=0%),达到了预设的非劣效性阈值。TNK溶栓与90天后无症状性脑内出血(0.00(95% CI -0.01至0.01);I2=0%)或死亡(0.01(95% CI -0.01至0.02);I2=0%)风险的增加无关。仅对0.25 mg/kg试验进行的敏感性分析显示出与主要分析相似的结果:在治疗AIS患者时,TNK与阿替普酶相比,在90天后获得极佳功能预后方面并无劣势,且不会增加患者的安全顾虑。这些研究结果表明,TNK可以替代阿替普酶:CRD42022354342。
{"title":"Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials.","authors":"Yunyun Xiong, Liyuan Wang, Guangshuo Li, Kai-Xuan Yang, Manjun Hao, Shuya Li, Yuesong Pan, Yongjun Wang","doi":"10.1136/svn-2023-002396","DOIUrl":"10.1136/svn-2023-002396","url":null,"abstract":"<p><strong>Background: </strong>Tenecteplase (TNK) was found non-inferior to alteplase in recent clinical trials. We aimed to elucidate the efficacy and safety of TNK versus alteplase for acute ischaemic stroke (AIS).</p><p><strong>Methods: </strong>Systematic literature search and a meta-analysis of phase III clinical trials in ischaemic stroke patients with TNK use were conducted. The primary outcome was excellent functional outcome which was defined as modified Rankin Scale score of 0-1 at 90 days and safety outcomes included symptomatic intracerebral haemorrhage and death at 90 days. We used random-effects model to estimate the pooled risk difference and 95% CI in R package 'Meta'. The included trials were adapted to the non-inferiority analysis with a margin of -4%.</p><p><strong>Results: </strong>Three trials enrolling 4094 patients were identified by systematic search. All trials included AIS patients within 4.5 hours time window. Meta-analysis indicated that 1089 (53.0%) of 2056 patients in the TNK arm and 1016 (50.5%) of 2012 in the alteplase arm had excellent functional outcome at 90 days (0.03 (95% CI -0.00 to 0.06); I<sup>2</sup>=0%), meeting the prespecified non-inferiority threshold. And TNK thrombolysis was not correlated with increased risk of symptomatic intracerebral haemorrhage (0.00 (95% CI -0.01 to 0.01); I<sup>2</sup>=0%) or death (0.01 (95% CI -0.01 to 0.02); I<sup>2</sup>=0%) at 90 days. The sensitivity analysis with the 0.25 mg/kg trials exclusively showed similar results to the main analysis.</p><p><strong>Conclusions: </strong>TNK was non-inferior to alteplase for achieving excellent functional outcome at 90 days without increasing the safety concern in treating patients with AIS. These findings suggest that TNK can be an alternative to alteplase.</p><p><strong>Prospero registration number: </strong>CRD42022354342.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"360-366"},"PeriodicalIF":4.4,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10102268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
He Liu, Conghui Li, Shaohua Ren, Tong Li, Hongliang Zhong, Jianwen Jia, Hongchao Yang, Yi Qi, Junqiang Feng, Youxiang Li, Yang Wang
Background: At present, neurointerventional surgery requires angiographers to perform operations in the digital subtraction angiography (DSA) room. Ionising radiation and chronic joint damage are still unavoidable for angiographers. Therefore, we researched and developed a neurointerventional robot-assisted system, which is operated by angiographers in an operating room outside the DSA room. We have conducted a prospective, multicentre, randomised controlled trial to evaluate the safety and efficacy of a robot-assisted system in human cerebral angiography. In the future, this research will provide a platform for the research and development of an intelligent surgical system and bring revolutionary progress in neurointerventional surgery.
Methods: From December 2020 to December 2021, 260 patients were enrolled from three medical centres, who were randomly and equally divided into a robot-assisted system group and a clinical routine cerebral angiography group. The success rate of angiography, the rate of the catheter reaching the target vessel, the operation time, X-ray radiation exposure and the incidence of related adverse events were compared between the two groups.
Results: A total of 257 patients completed this trial; baseline characteristics of the two groups did not differ significantly. The success rate of angiography in both the control group and the experimental group was 100%. The rate of the catheter reaching the target vessel was 99.23% and 100.00% in the control and experimental groups, respectively. For the control versus experimental groups, the angiographic operation time was 48.59±25.60 min versus 47.94±27.49 min, respectively; the X-ray radiation dose was 735.01±554.77 mGy versus 821.65±705.45 mGy, respectively; and the incidence of adverse events was 23.44% versus 22.48%, respectively. No statistical differences were present between the two groups.
Conclusion: The robot-assisted surgical system is more convenient for cerebral angiography and is as safe and effective as the traditional cerebral angiography.
{"title":"Efficacy and safety of a neurointerventional operation robotic assistance system in cerebral angiography.","authors":"He Liu, Conghui Li, Shaohua Ren, Tong Li, Hongliang Zhong, Jianwen Jia, Hongchao Yang, Yi Qi, Junqiang Feng, Youxiang Li, Yang Wang","doi":"10.1136/svn-2022-002260","DOIUrl":"10.1136/svn-2022-002260","url":null,"abstract":"<p><strong>Background: </strong>At present, neurointerventional surgery requires angiographers to perform operations in the digital subtraction angiography (DSA) room. Ionising radiation and chronic joint damage are still unavoidable for angiographers. Therefore, we researched and developed a neurointerventional robot-assisted system, which is operated by angiographers in an operating room outside the DSA room. We have conducted a prospective, multicentre, randomised controlled trial to evaluate the safety and efficacy of a robot-assisted system in human cerebral angiography. In the future, this research will provide a platform for the research and development of an intelligent surgical system and bring revolutionary progress in neurointerventional surgery.</p><p><strong>Methods: </strong>From December 2020 to December 2021, 260 patients were enrolled from three medical centres, who were randomly and equally divided into a robot-assisted system group and a clinical routine cerebral angiography group. The success rate of angiography, the rate of the catheter reaching the target vessel, the operation time, X-ray radiation exposure and the incidence of related adverse events were compared between the two groups.</p><p><strong>Results: </strong>A total of 257 patients completed this trial; baseline characteristics of the two groups did not differ significantly. The success rate of angiography in both the control group and the experimental group was 100%. The rate of the catheter reaching the target vessel was 99.23% and 100.00% in the control and experimental groups, respectively. For the control versus experimental groups, the angiographic operation time was 48.59±25.60 min versus 47.94±27.49 min, respectively; the X-ray radiation dose was 735.01±554.77 mGy versus 821.65±705.45 mGy, respectively; and the incidence of adverse events was 23.44% versus 22.48%, respectively. No statistical differences were present between the two groups.</p><p><strong>Conclusion: </strong>The robot-assisted surgical system is more convenient for cerebral angiography and is as safe and effective as the traditional cerebral angiography.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"243-251"},"PeriodicalIF":4.4,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10115407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xin Zhang, Yu Lei, Jiabin Su, Chao Gao, Yanjiang Li, Rui Feng, Ding Xia, Peng Gao, Yuxiang Gu, Ying Mao
Background: Although bypass surgery is an effective treatment for moyamoya vasculopathy (MMV), the incidence of postoperative complications is still high. This study aims to introduce a novel evaluating system based on individualised pathophysiology of MMV, and to assess its clinical significance.
Methods: This multicentre, prospective study enrolled adult patients with MMV from Huashan Hospital, Fudan University and National Center for Neurological Disorders, China between March 2021 and February 2022. Multimodal neuroimages containing structural and functional information were used to evaluate personalised disease severity and fused to localise the surgical field, avoid invalid regions and propose alternative recipient arteries. The recipient artery was further selected intraoperatively by assessing regional haemodynamic and electrophysiological information. The preanastomosis and postanastomosis data were compared with assist with the postoperative management. Patients who received such tailored revascularisations were included in the novel group and the others were included in the traditional group. The 30-day surgical outcomes and intermediate long-term follow-up were compared.
Results: Totally 375 patients (145 patients in the novel group and 230 patients in the traditional group) were included. The overall complication rate was significantly lower in the novel group (p˂0.001). In detail, both the rates of postoperative infarction (p=0.009) and hyperperfusion syndrome (p=0.010) were significantly lower. The functional outcomes trended to be more favourable in the novel group, though not significantly (p=0.260). Notably, the proportion of good functional status was higher in the novel group (p=0.009). Interestingly, the preoperative statuses of perfusion and metabolism around the bypass area were significantly correlated with the occurrence of postoperative complications (P˂0.0001).
Conclusions: This novel evaluating system helps to identify appropriate surgical field and recipient arteries during bypass surgery for MMV to achieve better haemodynamic remodelling and pathophysiological improvement, which results in more favourable clinical outcomes.
{"title":"Individualised evaluation based on pathophysiology for moyamoya vasculopathy: application in surgical revascularisation.","authors":"Xin Zhang, Yu Lei, Jiabin Su, Chao Gao, Yanjiang Li, Rui Feng, Ding Xia, Peng Gao, Yuxiang Gu, Ying Mao","doi":"10.1136/svn-2023-002464","DOIUrl":"10.1136/svn-2023-002464","url":null,"abstract":"<p><strong>Background: </strong>Although bypass surgery is an effective treatment for moyamoya vasculopathy (MMV), the incidence of postoperative complications is still high. This study aims to introduce a novel evaluating system based on individualised pathophysiology of MMV, and to assess its clinical significance.</p><p><strong>Methods: </strong>This multicentre, prospective study enrolled adult patients with MMV from Huashan Hospital, Fudan University and National Center for Neurological Disorders, China between March 2021 and February 2022. Multimodal neuroimages containing structural and functional information were used to evaluate personalised disease severity and fused to localise the surgical field, avoid invalid regions and propose alternative recipient arteries. The recipient artery was further selected intraoperatively by assessing regional haemodynamic and electrophysiological information. The preanastomosis and postanastomosis data were compared with assist with the postoperative management. Patients who received such tailored revascularisations were included in the novel group and the others were included in the traditional group. The 30-day surgical outcomes and intermediate long-term follow-up were compared.</p><p><strong>Results: </strong>Totally 375 patients (145 patients in the novel group and 230 patients in the traditional group) were included. The overall complication rate was significantly lower in the novel group (p˂0.001). In detail, both the rates of postoperative infarction (p=0.009) and hyperperfusion syndrome (p=0.010) were significantly lower. The functional outcomes trended to be more favourable in the novel group, though not significantly (p=0.260). Notably, the proportion of good functional status was higher in the novel group (p=0.009). Interestingly, the preoperative statuses of perfusion and metabolism around the bypass area were significantly correlated with the occurrence of postoperative complications (P˂0.0001).</p><p><strong>Conclusions: </strong>This novel evaluating system helps to identify appropriate surgical field and recipient arteries during bypass surgery for MMV to achieve better haemodynamic remodelling and pathophysiological improvement, which results in more favourable clinical outcomes.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"268-278"},"PeriodicalIF":4.4,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10119997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and purpose: Recent observational studies have reported that serum total homocysteine (tHcy) is associated with intracranial aneurysms (IAs). However, the causal effect of tHcy on IAs is unknown. We leveraged large-scale genetic association and real-world data to investigate the causal effect of tHcy on IA formation.
Methods: We performed a two-sample Mendelian randomisation (MR) using publicly available genome-wide association studies summary statistics to investigate the causal relationship between tHcy and IAs, following the recommendations of the Strengthening the Reporting of Observational Studies in Epidemiology-MR statement. Furthermore, a propensity score matching (PSM) analysis was conducted to evaluate the detailed effects of tHcy on risk of IA formation by utilizing real-world multicentre data, including 9902 patients with and without IAs (1:1 matched). Further interaction and subgroup analyses were performed to elucidate how tHcy affects risk of IA formation.
Results: MR analyses indicated that genetically determined tHcy was causally associated with IA risk (OR, 1.38, 95% CI 1.07 to 1.79; p=0.018). This is consistent with the more conservative weighted median analysis (OR, 1.41, 95% CI 1.03 to 1.93; p=0.039). Further sensitivity analyses showed no evidence of horizontal pleiotropy or heterogeneity of single nucleotide polymorphisms in causal inference. According to the PSM study, we found that, compared with low tHcy (≤15 µmol/L), moderate tHcy (>15-30 µmol/L) (OR 2.13, 95% CI 1.93 to 2.36) and high tHcy (>30 µmol/L) (OR 3.66, 95% CI 2.71 to 4.95) were associated with a higher IA risk (p trend <0.001). Subgroup analyses demonstrated significant ORs of tHcy in each subgroup when stratified by traditional cardiovascular risk factors. Furthermore, there was also a synergistic effect of tHcy and hypertension on IA risk (p interaction <0.001; the relative excess risk due to interaction=1.65, 95% CI 1.29 to 2.01).
Conclusion: Both large-scale genetic evidence and multicentre real-world data support a causal association between tHcy and risk of IA formation. Serum tHcy may serve as a biomarker to identify high-risk individuals who would particularly benefit from folate supplementation.
背景和目的:最近的观察性研究报告称,血清总同型半胱氨酸(tHcy)与颅内动脉瘤(IAs)有关。然而,tHcy 对动脉瘤的因果关系尚不清楚。我们利用大规模遗传关联和真实世界的数据,研究了tHcy对IA形成的因果效应:方法:根据《加强流行病学观察性研究报告--MR声明》的建议,我们利用公开的全基因组关联研究摘要统计数据进行了双样本孟德尔随机化(MR),以研究 tHcy 与 IAs 之间的因果关系。此外,该研究还进行了倾向得分匹配(PSM)分析,利用现实世界中的多中心数据(包括9902名患有和未患有IA的患者(1:1匹配))评估tHcy对IA形成风险的详细影响。还进行了进一步的交互分析和亚组分析,以阐明 tHcy 如何影响 IA 的形成风险:MR分析表明,由基因决定的tHcy与IA风险存在因果关系(OR,1.38,95% CI 1.07至1.79;P=0.018)。这与更为保守的加权中位数分析结果一致(OR,1.41,95% CI 1.03 至 1.93;P=0.039)。进一步的敏感性分析表明,在因果推断中没有证据表明单核苷酸多态性存在水平多义性或异质性。根据 PSM 研究,我们发现与低 tHcy(≤15 µmol/L)相比,中度 tHcy(>15-30 µmol/L)(OR 2.13,95% CI 1.93 至 2.36)和高度 tHcy(>30 µmol/L)(OR 3.66,95% CI 2.71 至 4.95)与较高的 IA 风险相关(P 趋势 结论):大规模遗传学证据和多中心真实世界数据均支持 tHcy 与 IA 形成风险之间存在因果关系。血清 tHcy 可作为一种生物标志物,用于识别高风险人群,这些人群将特别受益于叶酸的补充。
{"title":"A Mendelian randomisation, propensity score matching study to investigate causal association between serum homocysteine and intracranial aneurysm.","authors":"Zhuohua Wen, Xin Feng, Xin Tong, Chao Peng, Anqi Xu, Haiyan Fan, Yiming Bi, Wenchao Liu, Zhenjun Li, Shenquan Guo, Fa Jin, Ran Li, Yanchao Liu, Shixing Su, Xin Zhang, Xifeng Li, Xuying He, Aihua Liu, Chuanzhi Duan","doi":"10.1136/svn-2023-002414","DOIUrl":"10.1136/svn-2023-002414","url":null,"abstract":"<p><strong>Background and purpose: </strong>Recent observational studies have reported that serum total homocysteine (tHcy) is associated with intracranial aneurysms (IAs). However, the causal effect of tHcy on IAs is unknown. We leveraged large-scale genetic association and real-world data to investigate the causal effect of tHcy on IA formation.</p><p><strong>Methods: </strong>We performed a two-sample Mendelian randomisation (MR) using publicly available genome-wide association studies summary statistics to investigate the causal relationship between tHcy and IAs, following the recommendations of the Strengthening the Reporting of Observational Studies in Epidemiology-MR statement. Furthermore, a propensity score matching (PSM) analysis was conducted to evaluate the detailed effects of tHcy on risk of IA formation by utilizing real-world multicentre data, including 9902 patients with and without IAs (1:1 matched). Further interaction and subgroup analyses were performed to elucidate how tHcy affects risk of IA formation.</p><p><strong>Results: </strong>MR analyses indicated that genetically determined tHcy was causally associated with IA risk (OR, 1.38, 95% CI 1.07 to 1.79; p=0.018). This is consistent with the more conservative weighted median analysis (OR, 1.41, 95% CI 1.03 to 1.93; p=0.039). Further sensitivity analyses showed no evidence of horizontal pleiotropy or heterogeneity of single nucleotide polymorphisms in causal inference. According to the PSM study, we found that, compared with low tHcy (≤15 µmol/L), moderate tHcy (>15-30 µmol/L) (OR 2.13, 95% CI 1.93 to 2.36) and high tHcy (>30 µmol/L) (OR 3.66, 95% CI 2.71 to 4.95) were associated with a higher IA risk (p trend <0.001). Subgroup analyses demonstrated significant ORs of tHcy in each subgroup when stratified by traditional cardiovascular risk factors. Furthermore, there was also a synergistic effect of tHcy and hypertension on IA risk (p interaction <0.001; the relative excess risk due to interaction=1.65, 95% CI 1.29 to 2.01).</p><p><strong>Conclusion: </strong>Both large-scale genetic evidence and multicentre real-world data support a causal association between tHcy and risk of IA formation. Serum tHcy may serve as a biomarker to identify high-risk individuals who would particularly benefit from folate supplementation.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"202-211"},"PeriodicalIF":4.4,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9878544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and purpose: Multiple factors play important roles in the occurrence and prognosis of stroke. However, the roles of monogenic variants in all-cause ischaemic stroke have not been systematically investigated. We aim to identify underdiagnosed monogenic stroke in an adult ischaemic stroke/transient ischaemic attack (TIA) cohort (the Third China National Stroke Registry, CNSR-III).
Methods: Targeted next-generation sequencing for 181 genes associated with stroke was conducted on DNA samples from 10 428 patients recruited through CNSR-III. The genetic and clinical data from electronic health records (EHRs) were reviewed for completion of the diagnostic process. We assessed the percentages of individuals with pathogenic or likely pathogenic (P/LP) variants, and the diagnostic yield of pathogenic variants in known monogenic disease genes with associated phenotypes.
Results: In total, 1953 individuals harboured at least one P/LP variant out of 10 428 patients. Then, 792 (7.6%) individuals (comprising 759 individuals harbouring one P/LP variant in one gene, 29 individuals harbouring two or more P/LP variants in different genes and 4 individuals with two P/LP variants in ABCC6) were predicted to be at risk for one or more monogenic diseases based on the inheritance pattern. Finally, 230 of 792 individuals manifested a clinical phenotype in the EHR data to support the diagnosis of stroke with a monogenic cause. The most diagnosed Mendelian cause of stroke in the cohort was cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. There were no relationships between age or family history and the incidence of first symptomatic monogenic stroke in patients.
Conclusion: The rate of monogenic cause of stroke was 2.2% after reviewing the clinical phenotype. Possible reasons that Mendelian causes of stroke may be missed in adult patients who had an ischaemic stroke/TIA include a late onset of stroke symptoms, combination with common vascular risks and the absence of a prominent family history.
{"title":"Neglected Mendelian causes of stroke in adult Chinese patients who had an ischaemic stroke or transient ischaemic attack.","authors":"Wei Li, Hao Li, Chaoxia Lu, Jialu Zhao, Huichun Xu, Zhe Xu, Braxton Mitchell, Yong Jiang, Hong-Qiu Gu, Qin Xu, Anxin Wang, Xia Meng, Jinxi Lin, Jing Jing, Zixiao Li, Wanlin Zhu, Zhigang Liang, Mengxing Wang, Yongjun Wang","doi":"10.1136/svn-2022-002158","DOIUrl":"10.1136/svn-2022-002158","url":null,"abstract":"<p><strong>Background and purpose: </strong>Multiple factors play important roles in the occurrence and prognosis of stroke. However, the roles of monogenic variants in all-cause ischaemic stroke have not been systematically investigated. We aim to identify underdiagnosed monogenic stroke in an adult ischaemic stroke/transient ischaemic attack (TIA) cohort (the Third China National Stroke Registry, CNSR-III).</p><p><strong>Methods: </strong>Targeted next-generation sequencing for 181 genes associated with stroke was conducted on DNA samples from 10 428 patients recruited through CNSR-III. The genetic and clinical data from electronic health records (EHRs) were reviewed for completion of the diagnostic process. We assessed the percentages of individuals with pathogenic or likely pathogenic (P/LP) variants, and the diagnostic yield of pathogenic variants in known monogenic disease genes with associated phenotypes.</p><p><strong>Results: </strong>In total, 1953 individuals harboured at least one P/LP variant out of 10 428 patients. Then, 792 (7.6%) individuals (comprising 759 individuals harbouring one P/LP variant in one gene, 29 individuals harbouring two or more P/LP variants in different genes and 4 individuals with two P/LP variants in <i>ABCC6</i>) were predicted to be at risk for one or more monogenic diseases based on the inheritance pattern. Finally, 230 of 792 individuals manifested a clinical phenotype in the EHR data to support the diagnosis of stroke with a monogenic cause. The most diagnosed Mendelian cause of stroke in the cohort was cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. There were no relationships between age or family history and the incidence of first symptomatic monogenic stroke in patients.</p><p><strong>Conclusion: </strong>The rate of monogenic cause of stroke was 2.2% after reviewing the clinical phenotype. Possible reasons that Mendelian causes of stroke may be missed in adult patients who had an ischaemic stroke/TIA include a late onset of stroke symptoms, combination with common vascular risks and the absence of a prominent family history.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"194-201"},"PeriodicalIF":4.4,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10234616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Angel Miraclin T, John Davis Prasad, George Abraham Ninan, Mahasampath Gowri, Deepti Bal, Atif Iqbal Ahmed Shaikh, Rohit N Benjamin, Appaswamy Thirumal Prabhakar, Ajith Sivadasan, Vivek Mathew, Sanjith Aaron
Background: Multiple cerebral venous sinus thrombosis (CVT) registries from various geographical regions indicate that female gender, the use of contraceptive pills, pregnancy and puerperium are important risk factors. In this study, we report the changes in the epidemiology of patients with CVT managed over the past 26 years.
Methods: The CMC Vellore CVT registry is a prospectively maintained database at the Christian Medical College, Vellore since January 1995. Stata software was used to analyse the data and assess the changes in the incidence, age and gender distribution over the previous 26 years.
Results: Among 1701 patients treated during the study period, 908 (53%) were women and 793 (47%) were men. The mean incidence of CVT was 49 per 100 000 admissions before 2010, which increased to 96 per 100 000 after 2010. Male gender had a higher odds of developing CVT (OR - 2.07 (CI 1.68 to 2.55, p<0.001). This could be attributed to the declining incidence of postpartum CVT after 2010 compared with the decade before 2010 (50% vs 20%). The mean age at presentation had increased from 24.5 to 33.2 years in the last decade.
Conclusions: There was a clear change in the gender pattern from being a condition with female preponderance, to one where equal or more men are being affected. Lower incidence of postpartum CVT cases could be the driving factor. An increase in the overall incidence of CVT cases was noted, probably due to a higher index of clinical suspicion and better diagnostic imaging modalities.
{"title":"Cerebral venous sinus thrombosis: changing trends in the incidence, age and gender (findings from the CMC Vellore CVT registry).","authors":"Angel Miraclin T, John Davis Prasad, George Abraham Ninan, Mahasampath Gowri, Deepti Bal, Atif Iqbal Ahmed Shaikh, Rohit N Benjamin, Appaswamy Thirumal Prabhakar, Ajith Sivadasan, Vivek Mathew, Sanjith Aaron","doi":"10.1136/svn-2023-002351","DOIUrl":"10.1136/svn-2023-002351","url":null,"abstract":"<p><strong>Background: </strong>Multiple cerebral venous sinus thrombosis (CVT) registries from various geographical regions indicate that female gender, the use of contraceptive pills, pregnancy and puerperium are important risk factors. In this study, we report the changes in the epidemiology of patients with CVT managed over the past 26 years.</p><p><strong>Methods: </strong>The CMC Vellore CVT registry is a prospectively maintained database at the Christian Medical College, Vellore since January 1995. Stata software was used to analyse the data and assess the changes in the incidence, age and gender distribution over the previous 26 years.</p><p><strong>Results: </strong>Among 1701 patients treated during the study period, 908 (53%) were women and 793 (47%) were men. The mean incidence of CVT was 49 per 100 000 admissions before 2010, which increased to 96 per 100 000 after 2010. Male gender had a higher odds of developing CVT (OR - 2.07 (CI 1.68 to 2.55, p<0.001). This could be attributed to the declining incidence of postpartum CVT after 2010 compared with the decade before 2010 (50% vs 20%). The mean age at presentation had increased from 24.5 to 33.2 years in the last decade.</p><p><strong>Conclusions: </strong>There was a clear change in the gender pattern from being a condition with female preponderance, to one where equal or more men are being affected. Lower incidence of postpartum CVT cases could be the driving factor. An increase in the overall incidence of CVT cases was noted, probably due to a higher index of clinical suspicion and better diagnostic imaging modalities.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"252-257"},"PeriodicalIF":4.4,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10115409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kun Dai, Zongqi Wang, Bixi Gao, Longyuan Li, Feng Gu, Xinyu Tao, Wanchun You, Zhong Wang
Background: Subarachnoid haemorrhage (SAH) can result in a highly unfavourable prognosis. In recent years, the study of SAH has focused on early brain injury (EBI), which is a crucial progress that contributes to adverse prognosis. SAH can lead to various complications, including mitochondrial dysfunction and DNA damage. Apurinic/apyrimidinic endonuclease 1 (APE1) is an essential protein with multifaceted functionality integral to DNA repair and redox signalling. However, the role of APE1 in mitochondrial DNA damage repair after SAH is still unclear.
Methods: Our study involved an in vivo endovascular perforation model in rats and an in vitro neuron oxyhaemoglobin intervention. Then, the effects of APE1 on mitochondrial DNA damage repair were analysed by western blot, immunofluorescence, quantitative real-time PCR, mitochondrial bioenergetics measurement and neurobehavioural experiments.
Results: We found that the level of APE1 decreased while the mitochondria DNA damage and neuronal death increased in a rat model of SAH. Overexpression of APE1 improved short-term and long-term behavioural impairment in rats after SAH. In vitro, after primary neurons exposed to oxyhaemoglobin, APE1 expression significantly decreased along with increased mitochondrial DNA damage, a reduction in the subunit of respiratory chain complex levels and subsequent respiratory chain dysfunction. Overexpression of APE1 relieved energy metabolism disorders in the mitochondrial of neurons and reduced neuronal apoptosis.
Conclusion: In conclusion, APE1 is involved in EBI after SAH by affecting mitochondrial apoptosis via the mitochondrial respiratory chain. APE1 may potentially play a vital role in the EBI stage after SAH, making it a critical target for treatment.
背景:蛛网膜下腔出血(SAH)可导致非常不利的预后。近年来,对蛛网膜下腔出血的研究主要集中在早期脑损伤(EBI)上,这是导致预后不良的关键因素。SAH 可导致多种并发症,包括线粒体功能障碍和 DNA 损伤。Apurinic/apyrimidinic endonuclease 1(APE1)是一种重要的蛋白质,具有DNA修复和氧化还原信号不可或缺的多方面功能。然而,APE1 在 SAH 后线粒体 DNA 损伤修复中的作用仍不清楚:我们的研究涉及体内大鼠血管内穿孔模型和体外神经元氧合血红蛋白干预。然后,通过 Western 印迹、免疫荧光、定量实时 PCR、线粒体生物能测定和神经行为实验分析 APE1 对线粒体 DNA 损伤修复的影响:结果:我们发现,在 SAH 大鼠模型中,APE1 水平下降,而线粒体 DNA 损伤和神经元死亡增加。过表达 APE1 可改善 SAH 后大鼠的短期和长期行为损伤。在体外,原发性神经元暴露于氧合血红蛋白后,APE1的表达显著下降,线粒体DNA损伤增加,呼吸链复合物亚基水平降低,呼吸链功能随之失调。过表达 APE1 可缓解神经元线粒体的能量代谢紊乱,减少神经元凋亡:总之,APE1 通过线粒体呼吸链影响线粒体凋亡,从而参与 SAH 后的 EBI。APE1 有可能在 SAH 后的 EBI 阶段发挥重要作用,使其成为治疗的关键靶点。
{"title":"APE1 regulates mitochondrial DNA damage repair after experimental subarachnoid haemorrhage in vivo and in vitro.","authors":"Kun Dai, Zongqi Wang, Bixi Gao, Longyuan Li, Feng Gu, Xinyu Tao, Wanchun You, Zhong Wang","doi":"10.1136/svn-2023-002524","DOIUrl":"10.1136/svn-2023-002524","url":null,"abstract":"<p><strong>Background: </strong>Subarachnoid haemorrhage (SAH) can result in a highly unfavourable prognosis. In recent years, the study of SAH has focused on early brain injury (EBI), which is a crucial progress that contributes to adverse prognosis. SAH can lead to various complications, including mitochondrial dysfunction and DNA damage. Apurinic/apyrimidinic endonuclease 1 (APE1) is an essential protein with multifaceted functionality integral to DNA repair and redox signalling. However, the role of APE1 in mitochondrial DNA damage repair after SAH is still unclear.</p><p><strong>Methods: </strong>Our study involved an in vivo endovascular perforation model in rats and an in vitro neuron oxyhaemoglobin intervention. Then, the effects of APE1 on mitochondrial DNA damage repair were analysed by western blot, immunofluorescence, quantitative real-time PCR, mitochondrial bioenergetics measurement and neurobehavioural experiments.</p><p><strong>Results: </strong>We found that the level of APE1 decreased while the mitochondria DNA damage and neuronal death increased in a rat model of SAH. Overexpression of APE1 improved short-term and long-term behavioural impairment in rats after SAH. In vitro, after primary neurons exposed to oxyhaemoglobin, APE1 expression significantly decreased along with increased mitochondrial DNA damage, a reduction in the subunit of respiratory chain complex levels and subsequent respiratory chain dysfunction. Overexpression of APE1 relieved energy metabolism disorders in the mitochondrial of neurons and reduced neuronal apoptosis.</p><p><strong>Conclusion: </strong>In conclusion, APE1 is involved in EBI after SAH by affecting mitochondrial apoptosis via the mitochondrial respiratory chain. APE1 may potentially play a vital role in the EBI stage after SAH, making it a critical target for treatment.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"230-242"},"PeriodicalIF":4.4,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10115408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Aspirin is widely used for preventing ischaemic events. About 20%-40% of patients have aspirin resistance (ASR), which prevents them from benefiting from aspirin medication. This study aimed to develop and validate a model based on single-nucleotide polymorphism (SNP) to distinguish ASR patients.
Methods: We included patients with spontaneous intracerebral haemorrhage and continuing antiplatelet therapy from a multicentre, prospective cohort study as the derivation cohort. Thromboelastography (inhibition of arachidonic acid channel<50%) was used to identify ASR. Genotyping was performed to identify the ASR-related SNP. Based on the result of the logistic analysis, the aspirin resistance in the Chinese population score (ASR-CN score) was established, and its accuracy was evaluated using the area under the curve (AUC). Patients receiving dual antiplatelet therapy for unruptured intracranial aneurysm embolism were prospectively included in the validation cohort. After embolism, 30-day ischaemic events, including ischaemic stroke, new or more frequent transient ischaemic attack, stent thrombosis and cerebrovascular death, were recorded.
Results: The derivation cohort included 212 patients (155 male patients and the median age as 59). 87 (41.0%) individuals were identified with ASR. The multivariate logistic analysis demonstrated six SNPs of GP1BA, TBXA2R, PTGS2 and NOS3 as risk factors related to ASR. The ASR-CN score integrating these SNPs performed well to discriminate ASR patients from non-ASR patients (AUC as 0.77). Based on the validation cohort of 372 patients receiving antiplatelet therapy after embolism (including 130 ASR patients), the ASR-CN score continued to distinguish ASR patients with good accuracy (AUC as 0.80). Patients with high a ASR-CN score were more likely to suffer from 30-day ischaemic events after embolism (OR, 1.28; 95% CI, 1.10 to 1.50; p=0.002).
Conclusion: GP1BA, TBXA2R, PTGS2 and NOS3 were SNPs related to ASR. The ASR-CN score is an effective tool to discriminate ASR patients, which may guide antiplatelet therapy.
背景:阿司匹林被广泛用于预防缺血性事件。约 20%-40% 的患者存在阿司匹林耐药性(ASR),这使他们无法从阿司匹林药物中获益。本研究旨在开发和验证一种基于单核苷酸多态性(SNP)的模型,以区分阿司匹林耐药患者:方法:我们从一项多中心前瞻性队列研究中纳入了自发性脑内出血并持续接受抗血小板治疗的患者作为衍生队列。血栓弹性成像(抑制花生四烯酸通道)结果:衍生队列包括 212 名患者(155 名男性患者,中位年龄为 59 岁)。87人(41.0%)被确认患有ASR。多变量逻辑分析表明,GP1BA、TBXA2R、PTGS2 和 NOS3 的六个 SNPs 是与 ASR 相关的风险因素。整合了这些 SNPs 的 ASR-CN 评分能很好地区分 ASR 患者和非 ASR 患者(AUC 为 0.77)。根据 372 名栓塞后接受抗血小板治疗的患者(包括 130 名 ASR 患者)组成的验证队列,ASR-CN 评分仍能准确区分 ASR 患者(AUC 为 0.80)。ASR-CN评分高的患者更有可能在栓塞后30天内发生缺血性事件(OR,1.28;95% CI,1.10-1.50;P=0.002):结论:GP1BA、TBXA2R、PTGS2 和 NOS3 是与 ASR 相关的 SNPs。ASR-CN评分是鉴别ASR患者的有效工具,可指导抗血小板治疗:临床试验注册:抗血小板脑出血外科治疗队列(唯一标识符:ChiCTR1900024406):ChiCTR1900024406,http://www.chictr.org.cn/edit.aspx?pid=40640&htm=4)。
{"title":"Model based on single-nucleotide polymorphism to discriminate aspirin resistance patients.","authors":"Qingyuan Liu, Shuaiwei Guo, Nuochuan Wang, Kaiwen Wang, Shaohua Mo, Xiong Li, Yanan Zhang, Hongwei He, Shuo Wang, Jun Wu","doi":"10.1136/svn-2022-002228","DOIUrl":"10.1136/svn-2022-002228","url":null,"abstract":"<p><strong>Background: </strong>Aspirin is widely used for preventing ischaemic events. About 20%-40% of patients have aspirin resistance (ASR), which prevents them from benefiting from aspirin medication. This study aimed to develop and validate a model based on single-nucleotide polymorphism (SNP) to distinguish ASR patients.</p><p><strong>Methods: </strong>We included patients with spontaneous intracerebral haemorrhage and continuing antiplatelet therapy from a multicentre, prospective cohort study as the derivation cohort. Thromboelastography (inhibition of arachidonic acid channel<50%) was used to identify ASR. Genotyping was performed to identify the ASR-related SNP. Based on the result of the logistic analysis, the aspirin resistance in the Chinese population score (ASR-CN score) was established, and its accuracy was evaluated using the area under the curve (AUC). Patients receiving dual antiplatelet therapy for unruptured intracranial aneurysm embolism were prospectively included in the validation cohort. After embolism, 30-day ischaemic events, including ischaemic stroke, new or more frequent transient ischaemic attack, stent thrombosis and cerebrovascular death, were recorded.</p><p><strong>Results: </strong>The derivation cohort included 212 patients (155 male patients and the median age as 59). 87 (41.0%) individuals were identified with ASR. The multivariate logistic analysis demonstrated six SNPs of <i>GP1BA, TBXA2R, PTGS2</i> and <i>NOS3</i> as risk factors related to ASR. The ASR-CN score integrating these SNPs performed well to discriminate ASR patients from non-ASR patients (AUC as 0.77). Based on the validation cohort of 372 patients receiving antiplatelet therapy after embolism (including 130 ASR patients), the ASR-CN score continued to distinguish ASR patients with good accuracy (AUC as 0.80). Patients with high a ASR-CN score were more likely to suffer from 30-day ischaemic events after embolism (OR, 1.28; 95% CI, 1.10 to 1.50; p=0.002).</p><p><strong>Conclusion: </strong><i>GP1BA, TBXA2R, PTGS2</i> and <i>NOS3</i> were SNPs related to ASR. The ASR-CN score is an effective tool to discriminate ASR patients, which may guide antiplatelet therapy.</p><p><strong>Clinical trial registration: </strong>Surgical Treatments of Antiplatelet Intracerebral Hemorrhage cohort (unique identifier: ChiCTR1900024406, http://www.chictr.org.cn/edit.aspx?pid=40640&htm=4).</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":" ","pages":"212-220"},"PeriodicalIF":4.4,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10011249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}